CA2405136C - Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents - Google Patents

Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents Download PDF

Info

Publication number
CA2405136C
CA2405136C CA002405136A CA2405136A CA2405136C CA 2405136 C CA2405136 C CA 2405136C CA 002405136 A CA002405136 A CA 002405136A CA 2405136 A CA2405136 A CA 2405136A CA 2405136 C CA2405136 C CA 2405136C
Authority
CA
Canada
Prior art keywords
compound
treatment
accordance
compounds
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002405136A
Other languages
English (en)
French (fr)
Other versions
CA2405136A1 (en
Inventor
Alissar Nehme
Richard L. Beard
Roshantha A. Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Therapeutics Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2405136A1 publication Critical patent/CA2405136A1/en
Application granted granted Critical
Publication of CA2405136C publication Critical patent/CA2405136C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002405136A 2000-04-04 2001-04-02 Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents Expired - Lifetime CA2405136C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54214800A 2000-04-04 2000-04-04
US09/542,148 2000-04-04
PCT/US2001/010410 WO2001074759A1 (en) 2000-04-04 2001-04-02 Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents

Publications (2)

Publication Number Publication Date
CA2405136A1 CA2405136A1 (en) 2001-10-11
CA2405136C true CA2405136C (en) 2009-06-16

Family

ID=24162539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002405136A Expired - Lifetime CA2405136C (en) 2000-04-04 2001-04-02 Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents

Country Status (10)

Country Link
US (1) US6387950B2 (https=)
EP (2) EP1650188A1 (https=)
JP (1) JP2003534246A (https=)
AT (1) ATE331703T1 (https=)
AU (1) AU2001253045A1 (https=)
CA (1) CA2405136C (https=)
DE (1) DE60121145T2 (https=)
ES (1) ES2267754T3 (https=)
TW (1) TWI281911B (https=)
WO (1) WO2001074759A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903121B1 (en) * 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
DE60136477D1 (de) * 2000-10-02 2008-12-18 Hoffmann La Roche Retinoide zur behandlung von emphysem
EP1935869A1 (en) * 2000-10-02 2008-06-25 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
US6620963B1 (en) 2002-09-19 2003-09-16 Allergan, Inc. TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY
WO2005093426A2 (en) * 2004-03-26 2005-10-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara)
BRPI0616454A2 (pt) 2005-09-30 2011-06-21 Vitae Pharmaceuticals, Inc. métodos de tratamento de cáncer
US20120238623A1 (en) * 2011-03-14 2012-09-20 Chandraratna Roshantha A Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
MX352727B (es) 2011-12-13 2017-12-06 Dartmouth College Tratamiento de trastorno autoinmune al usar agonistas de rxr.
MX391949B (es) 2015-03-31 2025-03-21 Syros Pharmaceuticals Inc Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.
WO2017075607A1 (en) 2015-10-31 2017-05-04 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of pxr agonists and thyroid hormones
DK3380086T3 (da) * 2015-11-25 2021-11-22 Io Therapeutics Inc Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
CA3016876C (en) 2016-03-10 2021-12-28 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
KR20180121983A (ko) 2016-03-10 2018-11-09 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
JP7034085B2 (ja) 2016-04-08 2022-03-11 サイロス ファーマシューティカルズ， インコーポレイテッド Ａｍｌ及びｍｄｓの治療のためのｒａｒａアゴニスト
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
KR20200029544A (ko) 2017-07-13 2020-03-18 아이오 테라퓨틱스, 인크. 암 면역요법을 위해 면역 조절제와 조합된 면역조절 레티노이드 및 렉시노이드 화합물
KR20200044889A (ko) * 2017-08-31 2020-04-29 아이오 테라퓨틱스, 인크. 암 면역요법을 위해 면역 조절제와 조합된 rar 선택적 작용제
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
MX2024006978A (es) 2021-12-07 2024-07-19 Io Therapeutics Inc Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+.
CN114703227B (zh) * 2022-01-27 2023-11-10 中国科学院生态环境研究中心 基于MCF-7细胞系构建的RARα效应物体外筛选方法
US11976021B2 (en) 2022-06-27 2024-05-07 Io Therapeutics, Inc. Synthesis of tetrahydronaphthalenols and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69224660C5 (de) 1991-12-18 2010-06-02 The Salk Institute For Biological Studies, La Jolla Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity

Also Published As

Publication number Publication date
CA2405136A1 (en) 2001-10-11
EP1268405B1 (en) 2006-06-28
JP2003534246A (ja) 2003-11-18
AU2001253045A1 (en) 2001-10-15
WO2001074759A1 (en) 2001-10-11
EP1268405A1 (en) 2003-01-02
EP1650188A1 (en) 2006-04-26
US6387950B2 (en) 2002-05-14
ATE331703T1 (de) 2006-07-15
US20010039293A1 (en) 2001-11-08
DE60121145D1 (de) 2006-08-10
DE60121145T2 (de) 2007-05-31
TWI281911B (en) 2007-06-01
ES2267754T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
CA2405136C (en) Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents
Göttlicher et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
US8101793B2 (en) Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
US8389538B2 (en) Rexinoid compound having alkoxy group
Mehndiratta et al. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression
RU2364589C2 (ru) Ингибиторы гистондезацетилазы из новых производных бензамида с сильной дифференцировочной и антипролиферативной активностью
AU730261B2 (en) Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
AU2001230929B2 (en) Aniline-derived ligands for the thyroid receptor
He et al. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer
CN1513839A (zh) 具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂
US11312680B2 (en) Method for treating a patient having a colon cancer
Mori et al. Development of retinoic acid receptor antagonists bearing trans-SF4-alkynyl structure as a linear linker
HK1091196A (en) Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents
US5703130A (en) Chalcone retinoids and methods of use of same
CN100455564C (zh) 组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
AU702423B2 (en) Chalcone retinoids and methods of use of same
US20040122080A1 (en) Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
US20070123592A1 (en) Terephthalamide peptidomimetic compounds and methods
EP1383491A2 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210406